The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Brendan Smith - Cowen and Company LLC - Analyst
: Great. Thanks for taking the questions, guys. Congrats on all the progress. Great to see. First, quickly, can you just remind us what kind of data,
maybe how many patients, and length of follow-up we can expect from this first TL1A data readout later this year, and then I'll have a follow-up.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 12, 2025 / 8:30PM, ABSI.OQ - Q2 2025 Absci Corp Earnings Call
Question: Brendan Smith - Cowen and Company LLC - Analyst
: Yes, that's great. And then just quickly on 201, can you just remind us what the current plan is from a formulation and dosing perspective? I
understand it's not going to be in the clinic until early next year. But do you have a sense of maybe how often you think you'd need to dose and
whether you'll do IV or subq, and just any important potential pivot points and development path ahead that's kind of driving some of those
decisions?
Question: Brendan Smith - Cowen and Company LLC - Analyst
: Okay, got it. And that subq is being developed internally?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 12, 2025 / 8:30PM, ABSI.OQ - Q2 2025 Absci Corp Earnings Call
Question: Brendan Smith - Cowen and Company LLC - Analyst
: Great. Thanks, guys
Question: Arseniy Shabashvili - Guggenheim Securities LLC - Analyst
: Thank you for taking our questions. On your early oncology programs, ABS-301 and 501, what are the next preclinical milestones? And what would
trigger advancement into IND-enabling studies? And can you also provide more detail on the competitive landscape and commercial ratio now
for these programs?
Question: Arseniy Shabashvili - Guggenheim Securities LLC - Analyst
: Understood. And maybe one more related question on 201. You previously talked about the potential development of ABS-201 for endometriosis.
Could you talk about your latest thinking on prioritizing the endometriosis indication versus alopecia?
Question: Arseniy Shabashvili - Guggenheim Securities LLC - Analyst
: Thank you.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 12, 2025 / 8:30PM, ABSI.OQ - Q2 2025 Absci Corp Earnings Call
Question: Debanjana Chatterjee - Jonestrading Institutional Services LLC - Analyst
: Hi. Sorry, I was on mute. Thanks for taking my question. So in terms of the ABS-201 data expected in the second half of 2026, could you tell us what
is the bar for good data in terms of hair density and terminal hair count improvement? How we should benchmark the data set?
Question: Debanjana Chatterjee - Jonestrading Institutional Services LLC - Analyst
: Sure. And maybe a quick follow-up. Are you able to share if this will be an open-label trial or this will be like a controlled one?
Question: Debanjana Chatterjee - Jonestrading Institutional Services LLC - Analyst
: Okay. Thank you so much.
Question: Steven Deckert - KeyBanc Capital Markets Inc. - Analyst
: Hey, guys, just given the expanded partnership with Almirall, we're wondering how much capacity you feel like you have for additional programs
and partnerships. Thanks.
Question: Steven Deckert - KeyBanc Capital Markets Inc. - Analyst
: Great. Thanks. You kind of mentioned it in a previous question, but I'm just hoping to get an update on the caldera region of HIV. Just anything
new with that program you can talk about. Thanks.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 12, 2025 / 8:30PM, ABSI.OQ - Q2 2025 Absci Corp Earnings Call
Question: Steven Deckert - KeyBanc Capital Markets Inc. - Analyst
: All right, thank you.
| 
